Multiple Myeloma [clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf]
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation [clinicaltrials:NCT00001561]Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia [clinicaltrials:NCT00001623]Comparing Treatments for Multiple Myeloma [clinicaltrials:NCT00001750]Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants [clinicaltrials:NCT00001830]The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers [clinicaltrials:NCT00001873]clinicaltrials:NCT00002548clinicaltrials:NCT00002849clinicaltrials:NCT00002850clinicaltrials:NCT00003838clinicaltrials:NCT00005624clinicaltrials:NCT00005792clinicaltrials:NCT00005834clinicaltrials:NCT00006184clinicaltrials:NCT00012350Blood and Marrow Transplant Clinical Research Network [clinicaltrials:NCT00023530]clinicaltrials:NCT00028600Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions [clinicaltrials:NCT00029224]Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies [clinicaltrials:NCT00036023]Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma [clinicaltrials:NCT00036140]Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia [clinicaltrials:NCT00037791]clinicaltrials:NCT00038090clinicaltrials:NCT00038233CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation [clinicaltrials:NCT00038818]A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma [clinicaltrials:NCT00039754]clinicaltrials:NCT00040937CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma [clinicaltrials:NCT00044018]Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer [clinicaltrials:NCT00047788]PS-341 (VELCADEā¢) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [clinicaltrials:NCT00048230]Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H [clinicaltrials:NCT00048412]T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant [clinicaltrials:NCT00048464]Cytogenetic Studies in Acute Leukemia and Multiple Myeloma [clinicaltrials:NCT00048958]Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies [clinicaltrials:NCT00050687]A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma [clinicaltrials:NCT00051116]clinicaltrials:NCT00053196clinicaltrials:NCT00056160A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma [clinicaltrials:NCT00057564]clinicaltrials:NCT00060632Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) [clinicaltrials:NCT00060645]Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure [clinicaltrials:NCT00062621]A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 [clinicaltrials:NCT00063726]
condition [clinicaltrials_vocabulary:condition]
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation [clinicaltrials:NCT00001561]Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia [clinicaltrials:NCT00001623]Comparing Treatments for Multiple Myeloma [clinicaltrials:NCT00001750]Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants [clinicaltrials:NCT00001830]The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers [clinicaltrials:NCT00001873]Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002502]Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer [clinicaltrials:NCT00002504]clinicaltrials:NCT00002548Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma [clinicaltrials:NCT00002552]Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma [clinicaltrials:NCT00002556]Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma [clinicaltrials:NCT00002599]High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse [clinicaltrials:NCT00002630]Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease [clinicaltrials:NCT00002652]Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma [clinicaltrials:NCT00002653]clinicaltrials:NCT00002657clinicaltrials:NCT00002678Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer [clinicaltrials:NCT00002742]Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation [clinicaltrials:NCT00002787]High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis [clinicaltrials:NCT00002810]High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies [clinicaltrials:NCT00002818]clinicaltrials:NCT00002849clinicaltrials:NCT00002850Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma [clinicaltrials:NCT00002878]Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma [clinicaltrials:NCT00002907]Decitabine in Treating Patients With Melanoma or Other Advanced Cancer [clinicaltrials:NCT00002980]Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002989]Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma [clinicaltrials:NCT00003007]Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss [clinicaltrials:NCT00003077]Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer [clinicaltrials:NCT00003082]Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors [clinicaltrials:NCT00003107]clinicaltrials:NCT00003116Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00003146]Interleukin-12 in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00003149]Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation [clinicaltrials:NCT00003153]Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers [clinicaltrials:NCT00003163]Bryostatin and Vincristine in B-Cell Malignancies [clinicaltrials:NCT00003166]Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00003195]Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma [clinicaltrials:NCT00003196]Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00003270]Combination Chemotherapy in Treating Patients With Advanced Cancer [clinicaltrials:NCT00003331]
condition browse [clinicaltrials_vocabulary:condition-browse]
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation [clinicaltrials:NCT00001561]Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia [clinicaltrials:NCT00001623]Comparing Treatments for Multiple Myeloma [clinicaltrials:NCT00001750]Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants [clinicaltrials:NCT00001830]The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers [clinicaltrials:NCT00001873]Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002502]Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer [clinicaltrials:NCT00002504]clinicaltrials:NCT00002548Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma [clinicaltrials:NCT00002552]Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma [clinicaltrials:NCT00002556]Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma [clinicaltrials:NCT00002599]High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse [clinicaltrials:NCT00002630]Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease [clinicaltrials:NCT00002652]Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma [clinicaltrials:NCT00002653]clinicaltrials:NCT00002657clinicaltrials:NCT00002678Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer [clinicaltrials:NCT00002742]Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation [clinicaltrials:NCT00002787]High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis [clinicaltrials:NCT00002810]High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies [clinicaltrials:NCT00002818]clinicaltrials:NCT00002849clinicaltrials:NCT00002850Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma [clinicaltrials:NCT00002878]Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma [clinicaltrials:NCT00002907]Decitabine in Treating Patients With Melanoma or Other Advanced Cancer [clinicaltrials:NCT00002980]Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002989]Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma [clinicaltrials:NCT00003007]Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss [clinicaltrials:NCT00003077]Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer [clinicaltrials:NCT00003082]Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors [clinicaltrials:NCT00003107]clinicaltrials:NCT00003116Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00003146]Interleukin-12 in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00003149]Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation [clinicaltrials:NCT00003153]Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers [clinicaltrials:NCT00003163]Bryostatin and Vincristine in B-Cell Malignancies [clinicaltrials:NCT00003166]Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00003195]Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma [clinicaltrials:NCT00003196]Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00003270]Combination Chemotherapy in Treating Patients With Advanced Cancer [clinicaltrials:NCT00003331]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
eligibility for clinicaltrials:NCT00660166 [clinicaltrials_resource:1786032b4154028328a3baf181228dd6]eligibility for clinicaltrials:NCT01228318 [clinicaltrials_resource:3bc15f98f2ce750934c216590829c8af]eligibility for clinicaltrials:NCT01020045 [clinicaltrials_resource:446bdc505c9e5bef6badf8a3c56d019f]eligibility for clinicaltrials:NCT00193557 [clinicaltrials_resource:68c3892ab6f8244494240501526e05a5]eligibility for clinicaltrials:NCT01421524 [clinicaltrials_resource:8cbc496d951237bc39b801e3fb728e9b]eligibility for clinicaltrials:NCT00897260 [clinicaltrials_resource:bd898d00e95cd1a014d2d424306fa584]eligibility for clinicaltrials:NCT00290095 [clinicaltrials_resource:c50c0c38d7a38336849bdc7d9c88c874]eligibility for clinicaltrials:NCT01596257 [clinicaltrials_resource:f828b9b180cc44b205a7c5854b07c8ee]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00660166 [clinicaltrials_resource:1786032b4154028328a3baf181228dd6]eligibility for clinicaltrials:NCT01228318 [clinicaltrials_resource:3bc15f98f2ce750934c216590829c8af]eligibility for clinicaltrials:NCT01020045 [clinicaltrials_resource:446bdc505c9e5bef6badf8a3c56d019f]eligibility for clinicaltrials:NCT00193557 [clinicaltrials_resource:68c3892ab6f8244494240501526e05a5]eligibility for clinicaltrials:NCT01421524 [clinicaltrials_resource:8cbc496d951237bc39b801e3fb728e9b]eligibility for clinicaltrials:NCT00897260 [clinicaltrials_resource:bd898d00e95cd1a014d2d424306fa584]eligibility for clinicaltrials:NCT00290095 [clinicaltrials_resource:c50c0c38d7a38336849bdc7d9c88c874]eligibility for clinicaltrials:NCT01596257 [clinicaltrials_resource:f828b9b180cc44b205a7c5854b07c8ee]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Multiple Myeloma [clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf]
Bio2RDF identifier
b494bb98e15106ec59d72f9432b560bf
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf
identifier
clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf
title
Multiple Myeloma
@en
type
label
Multiple Myeloma [clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf]
@en
Multiple Myeloma